Effect of consumption of Citrus aurantifolia (lemon) peel on the modulation of lipid metabolism in rats with induced fatty liver
DOI:
https://doi.org/10.12873/Keywords:
PPAR alpha, PPAR gamma, SREBP, Citrus aurantifoliaAbstract
Objectives: To evaluate the effect of the ingestion of powdered Citrus aurantifolia “lemon” peel on the modulation of lipid metabolism in rats with induced liver failure. Materials and methods: An experimental, prospective and analytical study was conducted in an animal model. 30 male Holtzman rats were used, which were randomly distributed into five groups (n=6). Powdered Citrus aurantifolia “lemon” peel was obtained by dehydration and pulverization, which was mixed with the balanced diet for the species. Treatment of groups I and II was normal diet and groups III, IV and V were with a diet mixed with powdered Citrus aurantifolia “lemon” peel at 1; 3 and 9% respectively. For 28 days, a 15% fructose solution with 5% alcohol was supplied in the drinking troughs of groups II to V; At the end of treatment, the patient was anesthetized with intraperitoneal pentobarbital for liver removal. Triglycerides, PPAR-α, PPAR-γ, and SREBP were determined in liver tissue. Results: Triglyceride concentrations in the groups receiving Citrus aurantifolia peel powder were lower compared to group II (p<0.05). In group V, which consumed a diet containing 9% Citrus aurantifolia “lemon” peel powder, an increase in PPAR-α and a decrease in PPAR-γ and SREBP were evident, with the latter being significant (p<0.05). Histologically, the groups treated with the powder showed progression of micro and macrovesicular steatosis, as well as ballooning degeneration, compared to group II, suggesting a paradoxical effect at the cellular level. Conclusion: Intake of Citrus aurantifolia “lemon” peel powder has a hepatoprotective effect expressed in lower levels of triglycerides and SREBP in liver tissue compared to ethanol and fructose consumption in rats.
References
1. Velasco José VRA, Lydia MJA, Marcos BGM, Óscar PFE, José BÁR. Enfermedad hepática por hígado graso no alcohólico ¿Dónde estamos y a dónde vamos? [Internet]. 2018. Available from: www.revistamedicamd.com
2. Instituto Nacional de Estadística e Informática. PERÚ Enfermedades No Transmisibles y Transmisibles, 2017. 2017. https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1526/index.html
3. Buso C, Galdame O, Figueroa J, Sersing LL, Ojeda M, Pesce V, et al. Síndrome metabólico, hígado graso no alcohólico y hepatocarcinoma. Actualización en Nutrición. 2020;21(2):43–9. https://www.revistasan.org.ar/pdf_files/trabajos/vol_21/num_2/RSAN_21_2_43.pdf
4. Lanuza F, Sapunar J, Hofmann E. Análisis crítico del tratamiento de la enfermedad hepática grasa no alcohólica. Rev Med Chil. 2018;146(8):894–901. http://dx.doi.org/10.4067/s0034-98872018000800894
5. Kong LZ, Chandimali N, Han YH, Lee DH, Kim JS, Kim SU, et al. Pathogenesis, early diagnosis, and therapeutic management of alcoholic liver disease. Int J Mol Sci. 2019 Jun 2;20(11). https://doi.org/10.3390/ijms20112712
6. Carvallo P, Carvallo E, Barbosa-Da-Silva S, Mandarim-De-Lacerda A, Del Sol M. NAFLD e Ingesta de Fructosa en Altas concentraciones. Una Revisión de la Literatura. International Journal of Morphology. 2017;35(2):676–83. http://dx.doi.org/10.4067/S0717-95022017000200047
7. Carvallo P, Carvallo E, Barbosa-Da-Silva S, Mandarim-De-Lacerda CA, Hernández A, Del Sol M. Efectos Metabólicos del Consumo Excesivo de Fructosa Añadida. Int J Morphol. 2019;37(3):1058–66. http://dx.doi.org/10.4067/S0717-95022019000301058
8. Teschke R. Alcoholic liver disease: Current mechanistic aspects with focus on their clinical relevance. Biomedicines. 2019 Sep 5;7(3):1–12. https://doi.org/10.3390/biomedicines7030068
9. Simón J, Casado-Andrés M, Goikoetxea-Usandizaga N, Serrano-Maciá M, Martínez-Chantar ML. Nutraceutical properties of polyphenols against liver diseases. Nutrients. 2020 Nov 1;12(11):1–19. https://doi.org/10.3390/nu12113517
10. Fuentes-Nerrio L, Acevedo-correa D, Gelvez-Ordoñez M. Alimentos funcionales: impacto y retos para el desarrollo y bienestar de la sociedad colombiana artículo de revisión. Vol. 13, Biotecnología en el Sector Agropecuario y Agroindustrial. http://dx.doi.org/10.18684/BSAA(13)140-149
11. Oboh G, Bello FO, Ademosun AO, Akinyemi AJ, Adewuni TM. Antioxidant, hypolipidemic, and anti-angiotensin-1-converting enzyme properties of lemon (Citrus limon) and lime (Citrus aurantifolia) juices. Comp Clin Path. 2015 Nov 1;24(6):1395–406. https://link.springer.com/article/10.1007/s00580-015-2088-x
12. Karim N, Jia Z, Zheng X, Cui S, Chen W. A recent review of citrus flavanone naringenin on metabolic diseases and its potential sources for high yield-production. Trends Food Sci Technol. 2018 Sep 1;79:35–54. https://doi.org/10.1016/j.tifs.2018.06.012
13. Chriscensia E, Wibowo EC, Enriko G, Chrisfian Wijaya O, Anania A, Sahamastuti T. Phytochemical Screening, Therapeutic Benefits, and Adverse Effects of Citrus aurantifolia - A Review. Indonesian Journal of Life Sciences [Internet]. 2020 Sep;2(2):55–69. Available from: http://journal.i3l.ac.id/ojs/index.php/IJLS/55
14. Loizzo MR, Tundis R, Bonesi M, Menichini F, De Luca D, Colica C, et al. Evaluation of Citrus aurantifolia peel and leaves extracts for their chemical composition, antioxidant and anti-cholinesterase activities. J Sci Food Agric. 2012 Dec;92(15):2960–7. https://doi.org/10.1002/jsfa.5708
15. Zhou T, Zhang YJ, Xu DP, Wang F, Zhou Y, Zheng J, et al. Protective effects of lemon juice on alcohol-induced liver injury in mice. Biomed Res Int. 2017;2017. https://doi.org/10.1155/2017/7463571
16. Oghenevwodokohwo Okoro I. Hepatoprotective effects of hydroethanol extracts of Citrus aurantifolia fruits in CCl4-induced hepatotoxic rats. Sokoto J Med Lab Sci. 2019;4(4):65–75. https://sokjmls.com.ng/index.php/SJMLS/article/view/170
17. Alwahsh SM, Xu M, Schultze FC, Wilting J, Mihm S, Raddatz D, et al. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS One. 2014 Aug 7;9(8). https://doi.org/10.1371/journal.pone.0104220
18. Liu N, Li X, Zhao P, Zhang X, Qiao O, Huang L, et al. A review of chemical constituents and health-promoting effects of citrus peels. Food Chem. 2021 Dec 15;365:1–13. https://doi.org/10.1016/j.foodchem.2021.130585
19. Mohib M, Afnan K, Paran TZ, Khan S, Sarker J, Hasan N, et al. Beneficial Role of Citrus Fruit Polyphenols Against Hepatic Dysfunctions: A Review. Vol. 15, Journal of Dietary Supplements. Taylor and Francis Ltd; 2018. p. 223–50. https://doi.org/10.1080/19390211.2017.1330301
20. Morrow NM, Burke AC, Samsoondar JP, Seigel KE, Wang A, Telford DE, et al. The citrus flavonoid nobiletin confers protection from metabolic dysregulation in high-fat-fed mice independent of AMPK. J Lipid Res. 2020;61(3):387–402. https://doi.org/10.1194/jlr.ra119000542
21. Yuk T, Kim Y, Yang J, Sung J, Jeong HS, Lee J. Nobiletin Inhibits Hepatic Lipogenesis via Activation of AMP-Activated Protein Kinase. Evidence-based Complementary and Alternative Medicine. 2018;2018. https://doi.org/10.1155/2018/7420265
22. Shu Y, He D, Li W, Wang M, Zhao S, Liu L, et al. Hepatoprotective effect of citrus aurantium l. Against apap-induced liver injury by regulating liver lipid metabolism and apoptosis. Int J Biol Sci. 2020;16(5):752–65. https://doi.org/10.7150/ijbs.40612
23. Takahashi N, Kang MS, Kuroyanagi K, Goto T, Hirai S, Ohyama K, et al. Auraptene, a citrus fruit compound, regulates gene expression as a PPARα agonist in HepG2 hepatocytes. Vol. 33, BioFactors. IOS Press; 2008. https://doi.org/10.1002/biof.5520330103
24. Wang J, Fu T, Dong R, Wang C, Liu K, Sun H, et al. Hepatoprotection of auraptene from the peels of citrus fruits against 17α-ethinylestradiol-induced cholestasis in mice by activating farnesoid X receptor. Food Funct. 2019 Jul 1;10(7):3839–50. https://doi.org/10.1039/c9fo00318e
Downloads
Published
License
Copyright (c) 2025 Nutrición Clínica y Dietética Hospitalaria
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los lectores pueden utilizar los textos publicados de acuerdo con la definición BOAI (Budapest Open Access Initiative)
How to Cite
